You are here

Leadership

Study Co-Principal Investigators

  • David Gandara, Director, Thoracic Oncology Program, UC Davis
  • Roy Herbst, Chief of Medical Oncology, Yale Cancer Center
  • Fred Hirsch, Professor of Medicine and Pathology & Associate Director for International Programs University of Colorado Cancer Center
  • Philip Mack, Assistant Adjunct Professor, Co-Leader Molecular Pharmacology, UC Davis Comprehensive Cancer Center
  • Vali Papadimitrakopoulou, Professor, Department of Thoracic/Head and Neck Medical Oncology, MD Anderson
  • Mary Redman, Associate Member, Fred Hutchinson Cancer Research Center; Lead Statistician, SWOG Lung Committee
  • Lawrence Schwartz, Chair of Radiology, Columbia University & Chair of SWOG Imaging Committee

Lung-MAP Trial Oversight Committee

  • (Co-Chair) Roy Herbst, Chief of Medical Oncology, Yale Cancer Center
  • (Co-Chair) Ellen Sigal, Chairperson and Founder, Friends of Cancer Research
  • Jeff Abrams, Associate Director, NCI-CTEP
  • Chuck Blanke, Group Chair, SWOG
  • Tony Coles, Former CEO, Onyx Pharmaceuticals
  • Gwen Fyfe, Former Vice President, Oncology Department, Genentech
  • David Gandara, Chair, Lung Committee, SWOG-UC Davis
  • Gary Gilliland, Dean and VP, Precision Medicine, University of Pennsylvania
  • Fred Hirsch, Professor of Medicine and Pathology & Associate Director for International Programs University of Colorado Cancer Center
  • Gary Kelloff, Special Advisor, NCI-DCTD
  • Liz Mansfield, Director, Personalized Medicine, CDRH, FDA
  • Vali Papadimitrakopoulou, Professor, Department of Thoracic/Head and Neck Medical Oncology, SWOG-MD Anderson
  • David Wholley, Executive Director, The Biomarkers Consortium, FNIH
  • Janet Woodcock, Director, CDER, FDA

Lung-MAP Drug Selection Committee

  • (Co-Chair) Roy Herbst, Associate Director, Translational Research, Yale
  • (Co-Chair) David Gandara, Director, Thoracic Oncology Program, UC Davis
  • David Rimm, Professor of Pathology and Medicine, Yale
  • Everett Vokes, Chair, Dept. of Medicine, University of Chicago
  • Fred Hirsch, Professor of Medicine and Pathology, University of Colorado Cancer Center
  • Garry Kelloff, Advisor to Associate Director, NCI
  • Glenwood Goss, Head, Division of Medical Oncology, University of Ottawa
  • Gwen Fyfe, Former Vice President, Oncology Department, Genentech
  • Ignacio Wistuba, Chair, Department of Translational Molecular Pathology, MD Anderson
  • Jack Welch, Head of Gastrointestinal and Nueroendocrine Cancers Therapeutics, NCI-CTEP
  • Jeff Bradley, Department of Radiation Oncology, Washington University in St. Louis
  • Kapil Dhingra, Managing Member, KAPital Consulting LLC
  • Kathy Albain, Professor of Medicine, Loyola
  • Mark Socinski, Director, Lung Cancer Section, UPMC
  • Pasi Janne, Scientific Director, Dana Farber Cancer Center
  • Peter Ho, Founder, Metastagen
  • Suresh Ramalingham, Chief of Thoracic Oncology, Emory
  • Vassiliki A. Papadimitrakopoulou, Professor, Department of Thoracic/Head and Neck Medical Oncology, MD Anderson
  • Jamie Zwiebel, Chief, Investigational Drug Branch, NCI-CTEP
  • Mary Redman, Biostatistics, SWOG, Fred Hutchinson Cancer Center
  • Dana Sparks, Director of Operations and Protocols, SWOG
  • Naoko Takebe, Senior Investigator, NCI-CTEP
  • Shakun Malik, Head, Thoracic, and Head and Neck Cancer Therapeutics, NCI-CTEP
  • Ellen Sigal, Chair and Founder, Friends of Cancer Research
  • Jeff Allen, Executive Director, Friends of Cancer Research
  • David Wholley, Executive Director, The Biomarkers Consortium, FNIH
  • Sonia Pearson-White, Scientific Program Manager, Oncology, FNIH
  • Caroline Sigman, President, CEO, CCS Associates
  • Vince Miller, Chief Medical Officer, Foundation Medicine
  • Matt Hawryluk, Director of Business Development, Foundation Medicine
  • Roman Yelensky, Director, Clinical Genomic Analysis, Foundation Medicine

Lung-MAP Public Affairs Committee

  • (Chair) Ryan Hohman, JD, Managing Director, Policy & Public Affairs, Friends of Cancer Research
  • (Vice Chair) Wendy Lawton, Communications and Public Relations Manager, SWOG
  • Richard Folkers, Director of Communications, FNIH
  • Alison Hendrie, Senior Vice President, Rubenstein Communications (on behalf of FNIH)
  • Alex Sturm, Account Executive, Rubenstein Communications (on behalf of FNIH)
  • Mary Pat Lancelotta, MBA, Vice President, Strategic Marketing, Foundation Medicine
  • Vikki Christian, Corporate Affairs, Amgen
  • Ayesha Bharmal, Global Media Relations Director, AstraZeneca
  • Jennifer Mills, PhD, MSW, MPH, Advocacy Relations, Genentech
  • Tracy Rossin, Director, External Communications, MedImmune
  • Katherine Reuter, Senior Manager, External Communications, Pfizer

     NIH/NCI

  • Mike Miller, Senior Science Writer, NCI
  • Lynn Cave, Scientific Program Analyst, NCI-CTEP
  • Holly Massett, PhD, Senior Behavioral Science Analyst, NCI-CTEP

     Lung-MAP Advocate Advisors

  • Laurie Fenton-Ambrose, President & CEO, Lung Cancer Alliance
  • Andrea Stern Ferris, President and Chairman, LUNGevity
  • David LeDuc, CFRE, Program Director, Free to Breathe
  • David Simpkins, MS, Vice President, Strategic Communications Planning, American Cancer Society
  • Scott Santarella, President and CEO, Addario Lung Cancer Foundation
  • Delia Naughton, Interim Vice President, Business Development, Lung Cancer Research Foundation
  • Anastasia Hagan, Acting Executive Director, Uniting Against Lung Cancer
  • Harold Wimmer, President & CEO, American Lung Association